ipsc derived nk cells pipeline insight

DelveInsight’s, “IPSC derived NK cells Pipeline Insight, 2026” report provides comprehensive insights about 12+ companies and 15+ pipeline drugs in IPSC derived NK cells pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

IPSC derived NK cells Understanding

IPSC derived NK cells Overview

iPSC-derived NK cells are natural killer immune cells generated from Induced Pluripotent Stem Cells (iPSCs), providing a scalable and standardized platform for next-generation cancer immunotherapy. They are produced through a controlled differentiation process in which iPSCs first develop into CD34⁺ hematopoietic progenitor cells and then mature into functional NK cells under cytokine stimulation, particularly Interleukin-15. During maturation, the cells express key cytotoxic molecules such as granzyme B (GZMB) and perforin (PRF1), enabling them to recognize and eliminate malignant cells, especially those lacking Human Leukocyte Antigen class I expression—a common immune-evasion strategy used by tumors. Compared with donor-derived NK cells, iPSC-derived NK cells minimize donor variability and support large-scale “off-the-shelf” manufacturing, while their stable genetic background allows precise engineering, including integration of Chimeric Antigen Receptor (CAR) constructs to enhance tumor targeting.

During differentiation, these cells undergo a structured maturation process that mirrors the natural development of Natural Killer Cells. The process begins with embryoid bodies that generate CD34⁺CD45⁺ hematopoietic progenitors, which gradually differentiate into NK lineage cells. As maturation progresses, the cells transition from loose aggregates to compact lymphoid populations with greater cytoplasmic complexity and granularity. Immature NK cells acquire characteristic markers such as CD56, CD161, and CD94, eventually developing a mature phenotype defined by CD56⁺CD16⁺CD3⁻ expression and activating receptors like NKp46. Morphologically, mature cells exhibit a high nucleus-to-cytoplasm ratio and contain azurophilic cytotoxic granules. Functionally, they form immunological synapses with target cells and release perforin and granzymes, a process supported by JAK-STAT5 signaling pathway activation that promotes NK-cell survival and activity.

As a therapeutic platform, iPSC-derived NK cells are being widely explored for both hematologic and solid tumors. Their scalable production enables standardized cell therapies for diseases such as Leukemia and Lymphoma, as well as other treatment-resistant malignancies. These engineered immune cells show potent cytotoxic activity against tumors that downregulate HLA class I molecules, including Lung Cancer, Ovarian Cancer, Melanoma, Myeloid Leukemia, and Hepatocellular Carcinoma. Genetic engineering approaches, particularly CAR integration, can further enhance their tumor specificity and persistence. Additionally, these NK cells may act synergistically with monoclonal antibodies and immune checkpoint inhibitors to strengthen antitumor immune responses, making them a promising strategy in next-generation cellular immunotherapy.

"IPSC derived NK cells Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the drug class. A detailed picture of the IPSC derived NK cells pipeline landscape is provided which includes the drug class and IPSC derived NK cells mechanism of action. The assessment part of the report embraces, in depth IPSC derived NK cells commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, IPSC derived NK cells collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest IPSC derived NK cells pipeline insights , emerging therapies, and clinical advancements shaping the future of treatment in 2026.

IPSC derived NK cells Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence IPSC derived NK cells R&D. The therapies under development are focused on novel approaches to treat/improve IPSC derived NK cells.

IPSC derived NK cells Emerging Drugs Analysis

This segment of the IPSC derived NK cells report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

IPSC derived NK cells Emerging Drugs

CNTY-101: Century Therapeutics, Inc.

CNTY-101 is an investigational, off-the-shelf cell therapy developed by Century Therapeutics, designed for the treatment of B-cell mediated autoimmune diseases. It is derived from induced pluripotent stem cells (iPSCs) and engineered into CD19-targeted chimeric antigen receptor natural killer (CAR-NK) cells. The therapy selectively depletes CD19-positive B cells, which are implicated in the pathogenesis of diseases such as systemic lupus erythematosus. CNTY-101 incorporates genetic modifications to enhance persistence, functionality, and resistance to immune rejection. As an allogeneic product, it aims to provide a scalable and readily available alternative to autologous cell therapies. Currently, CNTY-101 is being evaluated in Phase I/II trial in patients with B-cell mediated autoimmune diseases.

FT522: Fate Therapeutics

FT522 is an investigational, off-the-shelf CAR-NK cell therapy derived from Induced Pluripotent Stem Cells (iPSCs) and developed by Fate Therapeutics. The therapy is engineered with a Chimeric Antigen Receptor (CAR) that targets CD19 expressed on malignant B cells, enabling selective recognition and destruction of tumor cells. It also incorporates a proprietary Alloimmune Defense Receptor (ADR) designed to improve persistence by eliminating activated alloreactive immune cells that could otherwise reject the therapy. Manufactured as a cryopreserved allogeneic product, FT522 supports scalable production and immediate availability without the need for patient-specific cell collection. The therapy aims to deliver potent antitumor activity with improved durability and safety compared with conventional approaches. Currently, FT522 is being evaluated in Phase I clinical trials for the treatment of Relapsed/Refractory B‑Cell Lymphoma.

Further product details are provided in the report……..

IPSC derived NK cells Therapeutic Assessment

This segment of the report provides insights about the different IPSC derived NK cells drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in IPSC derived NK cells

There are approx. 12+ key companies which are developing the therapies for IPSC derived NK cells. The companies which have their IPSC derived NK cells drug candidates in the most advanced stage, i.e. Phase I/II include, Century Therapeutics, Inc.

IPSC derived NK cells Clinical Trial Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like

Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates

Route of Administration

IPSC derived NK cells pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Molecule Type

Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

IPSC derived NK cells Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

IPSC derived NK cells Clinical Trial Activities

The IPSC derived NK cells Pipeline Report provides insights into different IPSC derived NK cells Clinical Trials within phase II, I, preclinical and discovery stage. It also analyses IPSC derived NK cells therapeutic drugs key players involved in developing key drugs.

IPSC derived NK cells Pipeline Development Activities

The IPSC derived NK cells Clinical Trial Analysis Report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging IPSC derived NK cells drugs.

IPSC derived NK cells Report Insights

IPSC derived NK cells Pipeline Analysis
IPSC derived NK cells Therapeutic Assessment
IPSC derived NK cells Market Unmet Needs
Impact of IPSC derived NK cells Drugs

IPSC derived NK cells Report Assessment

IPSC derived NK cells Pipeline Product Profiles
IPSC derived NK cells Therapeutic Assessment
IPSC derived NK cells Pipeline Assessment
Inactive IPSC derived NK cells drugs assessment
IPSC derived NK cells Market Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:
How many companies are developing IPSC derived NK cells drugs?
How many IPSC derived NK cells drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of IPSC derived NK cells?
What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the IPSC derived NK cells therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for IPSC derived NK cells and their status?
What are the key designations that have been granted to the emerging drugs?

IPSC derived NK cells Key Players